MAZE | NASDAQ
$26.65
-$0.53 | -1.95%
SIGNAL:
|2026-09-30
|F&G 41
|RSI 51.6
|2026-09-30
|F&G 41
|RSI 51.6
Company Overview:
Market Cap:
$1.48B
Trailing PE:
N/A
FWD PE:
—
Payout Ratio (TTM):
—
52-Week Range:
$21.95 - $53.65
1.7 Year MAZE Performance Metrics:
Total Return (with DRIP):
67.1% (35.25% CAGR)
Total Return (no DRIP):
67.1% (35.25% CAGR)
Share Price:
67.1% (35.25% CAGR)
Yield on Cost (with DRIP):
—
Total Invested:
$10,000
Total Value (with DRIP):
$16,708
Total Return $ (with DRIP):
$6,708
MAZE Total Return
1M
3M
6M
YTD
1Y
3Y
5Y
10Y
MAZE Price Chart
1M
3M
6M
YTD
1Y
3Y
5Y
10Y
All
Unlock All Reports & Research Dividend Stocks like a BOSS!
Save 25% with annual plan (3 Months Free)
Save 25% with annual plan (3 Months Free)
PRO
$19/mo
$11.40/mo
7-day free trial
- Unlimited Portfolio Tracker
- Portfolio - Lots/Sales/Dividends
- Portfolio Auto-DRIP
- Buy/Sell Signals Dashboard
- Stock Fundamentals
- Compare Stocks Side-by-Side
- Revenue & EPS Estimates
- DCF Valuation Modeling
You save $7.60 (40%)
Most Popular
PREMIUM
$32/mo
$19.20/mo
7-day free trial
- Everything in Pro
- YieldMax PNL Tracker
- YieldMax NAV Erosion Alerts
- YM ETFs Trend Signals
- 9/21 EMA Trend Signals
- Stocks Dashboard
You save $12.80 (40%)
ULTRA
$64/mo
$38.40/mo
7-day free trial
- Everything in Premium
- 15min & 1hr Intraday Signals
- Group & weekly ETF estimates
- YouTuber Mode
- Trades summary + CSV export
- Priority data & support
You save $25.60 (40%)
PRO
$171 ($14.25/mo)
$102.60/yr ($8.55/mo)
7-day free trial
- Unlimited Portfolio Tracker
- Portfolio - Lots/Sales/Dividends
- Portfolio Auto-DRIP
- Buy/Sell Signals Dashboard
- Stock Fundamentals
- Compare Stocks Side-by-Side
- Revenue & EPS Estimates
- DCF Valuation Modeling
You save $125.40 (55%)
Most Popular
PREMIUM
$288 ($24/mo)
$172.80/yr ($14.40/mo)
7-day free trial
- Everything in Pro
- YieldMax PNL Tracker
- YieldMax NAV Erosion Alerts
- YM ETFs Trend Signals
- 9/21 EMA Trend Signals
- Stocks Dashboard
You save $211.20 (55%)
ULTRA
$576 ($48/mo)
$345.60/yr ($28.80/mo)
7-day free trial
- Everything in Premium
- 15min & 1hr Intraday Signals
- Group & weekly ETF estimates
- YouTuber Mode
- Trades summary + CSV export
- Priority data & support
You save $422.40 (55%)
MAZE Fundamentals: Earnings, Revenue, Cash Flow, Ebitda, Cash/Debt, Shares Float, etc:
MAZE Revenue CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
MAZE EPS CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
🔓 See the full chart40% off right now · 7-day free trial
MAZE Net Income CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
🔓 See the full chart40% off right now · 7-day free trial
MAZE EBITDA CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
🔓 See the full chart40% off right now · 7-day free trial
MAZE Free Cash Flow CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
🔓 See the full chart40% off right now · 7-day free trial
MAZE Free Cash Flow / Share CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
🔓 See the full chart40% off right now · 7-day free trial
MAZE Operating Income CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
🔓 See the full chart40% off right now · 7-day free trial
MAZE Gross Profit CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
🔓 See the full chart40% off right now · 7-day free trial
MAZE Shares Outstanding CAGR:1Y: 34.54%2Y: 16.07%5Y: 0.00%10Y: 0.00%
🔓 See the full chart40% off right now · 7-day free trial
MAZE Share Buybacks CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
🔓 See the full chart40% off right now · 7-day free trial
MAZE Stock-Based Comp CAGR:1Y: 183.81%2Y: 107.10%5Y: 0.00%10Y: 0.00%
🔓 See the full chart40% off right now · 7-day free trial
MAZE Expenses CAGR:1Y: -72.77%2Y: -18.22%5Y: 0.00%10Y: 0.00%
🔓 See the full chart40% off right now · 7-day free trial
🔓 See the full chart40% off right now · 7-day free trial
🔓 See the full chart40% off right now · 7-day free trial
🔓 See the full chart40% off right now · 7-day free trial
🔓 See the full chart40% off right now · 7-day free trial
🔓 See the full chart40% off right now · 7-day free trial
🔓 See the full chart40% off right now · 7-day free trial
MAZE Revenue CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:
🔓 See the full chart40% off right now · 7-day free trial
MAZE Actual Revenue CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
🔓 See the full chart40% off right now · 7-day free trial
MAZE Actual EPS CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
🔓 See the full chart40% off right now · 7-day free trial
MAZE Actual Net Income CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
🔓 See the full chart40% off right now · 7-day free trial
MAZE Actual EBITDA CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
Ratios, Profit Margins & Return on Capital:
🔓 See the full chart40% off right now · 7-day free trial
MAZE Net Profit Margin CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
🔓 See the full chart40% off right now · 7-day free trial
MAZE Gross Profit Margin CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
🔓 See the full chart40% off right now · 7-day free trial
MAZE Price to Earnings CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
🔓 See the full chart40% off right now · 7-day free trial
MAZE Price To Sales Ratio CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
🔓 See the full chart40% off right now · 7-day free trial
MAZE Return on Capital Employed CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
🔓 See the full chart40% off right now · 7-day free trial
MAZE Return on Invested Capital CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
Projected Future Returns & Dividends for MAZE
Based on past 1.7-year performance, here are MAZE growth metrics:
Share price CAGR of +35.25%
Dividend CAGR of +0%
Using MAZE CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:
| MAZE (DRIP) | MAZE - No DRIP | |
|---|---|---|
| Current Price | $26.65 | $26.65 |
| Start Shares | 375.23 | 375.23 |
| Start Value | $10,000 | $10,000 |
| After 10 years: | ||
| Final Share Count | 375.23 | 375.23 |
| Dividends Payment | $0.00 | $0.00 |
| Annual Dividends | $0 | $0 |
| Yield on cost | 0.00% | 0.00% |
| Share Price | $26.65 | $26.65 |
| Total Dividends | $0 | $0 |
| Final Value | $10,000 | $10,000 |
Estimated Future Value + Dividends - MAZE
NOTE: Above numbers are our estimate based on MAZE's Dividend and Price CAGR over past 1.7 years.
These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.
We cannot guarantee that your actual returns will meet these estimates.
Get the best Dividend Stock Research Tools:
Save 25% with annual plan (3 Months Free)
Save 25% with annual plan (3 Months Free)
PRO
$19/mo
$11.40/mo
7-day free trial
- Unlimited Portfolio Tracker
- Portfolio - Lots/Sales/Dividends
- Portfolio Auto-DRIP
- Buy/Sell Signals Dashboard
- Stock Fundamentals
- Compare Stocks Side-by-Side
- Revenue & EPS Estimates
- DCF Valuation Modeling
You save $7.60 (40%)
Most Popular
PREMIUM
$32/mo
$19.20/mo
7-day free trial
- Everything in Pro
- YieldMax PNL Tracker
- YieldMax NAV Erosion Alerts
- YM ETFs Trend Signals
- 9/21 EMA Trend Signals
- Stocks Dashboard
You save $12.80 (40%)
ULTRA
$64/mo
$38.40/mo
7-day free trial
- Everything in Premium
- 15min & 1hr Intraday Signals
- Group & weekly ETF estimates
- YouTuber Mode
- Trades summary + CSV export
- Priority data & support
You save $25.60 (40%)
PRO
$171 ($14.25/mo)
$102.60/yr ($8.55/mo)
7-day free trial
- Unlimited Portfolio Tracker
- Portfolio - Lots/Sales/Dividends
- Portfolio Auto-DRIP
- Buy/Sell Signals Dashboard
- Stock Fundamentals
- Compare Stocks Side-by-Side
- Revenue & EPS Estimates
- DCF Valuation Modeling
You save $125.40 (55%)
Most Popular
PREMIUM
$288 ($24/mo)
$172.80/yr ($14.40/mo)
7-day free trial
- Everything in Pro
- YieldMax PNL Tracker
- YieldMax NAV Erosion Alerts
- YM ETFs Trend Signals
- 9/21 EMA Trend Signals
- Stocks Dashboard
You save $211.20 (55%)
ULTRA
$576 ($48/mo)
$345.60/yr ($28.80/mo)
7-day free trial
- Everything in Premium
- 15min & 1hr Intraday Signals
- Group & weekly ETF estimates
- YouTuber Mode
- Trades summary + CSV export
- Priority data & support
You save $422.40 (55%)
Company Info
Maze Therapeutics, Inc. (MAZE) had its IPO on 2025-01-31, and is traded on NASDAQ stock exchange.
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
MAZE website: https://www.mazetx.com
Get Full Access to All Reports with DRIPCalc PRO
Save 25% with annual plan (3 Months Free)
Save 25% with annual plan (3 Months Free)
PRO
$19/mo
$11.40/mo
7-day free trial
- Unlimited Portfolio Tracker
- Portfolio - Lots/Sales/Dividends
- Portfolio Auto-DRIP
- Buy/Sell Signals Dashboard
- Stock Fundamentals
- Compare Stocks Side-by-Side
- Revenue & EPS Estimates
- DCF Valuation Modeling
You save $7.60 (40%)
Most Popular
PREMIUM
$32/mo
$19.20/mo
7-day free trial
- Everything in Pro
- YieldMax PNL Tracker
- YieldMax NAV Erosion Alerts
- YM ETFs Trend Signals
- 9/21 EMA Trend Signals
- Stocks Dashboard
You save $12.80 (40%)
ULTRA
$64/mo
$38.40/mo
7-day free trial
- Everything in Premium
- 15min & 1hr Intraday Signals
- Group & weekly ETF estimates
- YouTuber Mode
- Trades summary + CSV export
- Priority data & support
You save $25.60 (40%)
PRO
$171 ($14.25/mo)
$102.60/yr ($8.55/mo)
7-day free trial
- Unlimited Portfolio Tracker
- Portfolio - Lots/Sales/Dividends
- Portfolio Auto-DRIP
- Buy/Sell Signals Dashboard
- Stock Fundamentals
- Compare Stocks Side-by-Side
- Revenue & EPS Estimates
- DCF Valuation Modeling
You save $125.40 (55%)
Most Popular
PREMIUM
$288 ($24/mo)
$172.80/yr ($14.40/mo)
7-day free trial
- Everything in Pro
- YieldMax PNL Tracker
- YieldMax NAV Erosion Alerts
- YM ETFs Trend Signals
- 9/21 EMA Trend Signals
- Stocks Dashboard
You save $211.20 (55%)
ULTRA
$576 ($48/mo)
$345.60/yr ($28.80/mo)
7-day free trial
- Everything in Premium
- 15min & 1hr Intraday Signals
- Group & weekly ETF estimates
- YouTuber Mode
- Trades summary + CSV export
- Priority data & support
You save $422.40 (55%)
Loading signals…
DCF Model — MAZE
Value from:
🔒 Upgrade to unlock
The full DCF valuation — fair value, implied growth and the price path — is a paid feature.
Upgrade
Pay up to today
—
vs current price $26.65
—
Cash flow & implied price by year
FCF is negative or missing for this company (common for banks) — the model discounts EPS instead.
EPS is negative or missing for this company — Simple mode uses free cash flow per share instead.
Free cash flow today
—
grows for the next years
Then mature
—
every future dollar counted back to today
Pile of today-dollars
—
÷ shares
Implied price path
| Year | FCF | Implied price |
|---|
Sensitivity — fair value: growth ↓ × target return →
